Most of the ideasbi³will support will feature the following properties:
- Innovative biology with disease-modifying potential
- Drug prototypes: Lead-stage molecules that are no more than 3 – 4 years away from IND
- Milestone-driven research plan that outlines a clear path toward transition into development and can be completed in 2 to 3 years for a maximum of $10 M
- Relevant to a therapeutic area of interest to Biogen Idec: neurology, oncology, immunology, acute cardiovascular
- Protein-based therapeutic or a small molecule with well-characterized biology and a rational SAR strategy
- Committed scientists/founders willing to play a substantial role in the company